NZ company growing new skin for burn victims

A Kiwi biotechnology company which has found a way to grow bigger-than-A5 sheets of replacement human skin says the product might be ready to start clinical trials on burn patients in 2020 or 2021.

Upside Biotechnologies, a company which spun out of the University of Auckland’s immunology research area, announced this week it has raised $2 million in a convertible notes issue from existing investors.

And it is preparing for a $10m to $15m capital raising later this year, which will hopefully take it into clinical trials 12-15 months after that.

Read more

Please follow and like us:

Upside Biotechnologies wins $409k research grant

Upside Biotechnologies, a regenerative tissue developer spun out of Auckland University, has won a $409,000 research grant to prepare its PelliCel product for a clinical trial and deepening its existing relationship with the US Army.

Auckland-based Upside, which raised $2.3 million last year, won the Medical Technology Enterprise Consortium (MTEC) prototype acceleration award, it said in a statement. The biotech firm is developing an advanced skin replacement treatment for burn victims, enabling a small sample of unburnt skin to be grown in a lab and used as skin grafts for patients who don’t have enough uninjured skin for a conventional graft.

Read more

Please follow and like us:

Lead Partners

NZTE NZVIF PWC

Expert Partner

AVID “FNZC.jpg”

AANZ Summit Sponsors

Callaghan Innovation “UniServices” Kiwinet “Spark”